Table 1.

Clinical and laboratory characteristics of patients with recurrent AAU and healthy controls. Values are n (%) unless otherwise specified.

VariablesGroup 1, AxSpA, n = 20Group 2, NSBP, n = 6Group 3, Asymptomatic, n = 24Group 4, Controls, n = 21Group 5, AS, n = 30p
Female13 (75)0 (0)12 (50)14 (66.7)6 (20)0.921*
White11 (55)3 (50)14 (58.3)12 (57.1)1.000*
Age, yrs, mean ± SD44.8 ± 14.344.5 ± 11.242.3 ± 11.847.1 ± 1240.40 ± 110.378Δ
Age at onset of uveitis, yrs, mean ± SD38.9 ± 1435.5 ± 14.836.8 ± 12.8NANA0.817Δ
Eye disease duration, yr, mean ± SD6.2 ± 6.17.2 ± 6.25.5 ± 6.4NANA0.491
Active uveitis7 (35)2 (33.3)14 (58.3)NANA0.252*
Age at onset of back pain, yrs, mean ± SD31.2 ± 1030.5 ± 11.3NANANA0.893
Back pain duration, yrs, mean ± SD13.8 ± 10.514.8 ± 14.3NANA17 ± 11.520.629Δ
Inflammatory back pain (expert opinion/ASAS definition)9 (45)NANANA30 (100)
Assessment instruments, mean ± SDBASDAI 4.2 ± 2.3NANANABASDAI 4.9 ± 2.6,0.356
BASFI 2.9 ± 2.7BASFI 3.7 ± 2.80.296
BASMI 3.0 ± 1.2
ASDAS-ESR 3.1 ± 1.10.059
ASDAS-CRP 3.1 ± 1.1ASDAS-CRP 3.8 ± 1.3
Enthesitis score (MASES) ≥ 26 (30)1 (16.7)1 (4.17)0 (0)0.007*
ESR, mm/1st h, mean ± SD23.7 ± 189.5 ± 6.226.4 ± 22.4NA0.176Δ
CRP, mg/l, mean ± SD7.7 ± 9.22.5 ± 2.34.3 ± 4.7NA10.9 ± 10.60.014
HLA-B27+12 (60)0 (0)12 (50)NA26 (87)0.025*
  • * Fisher’s exact test;

  • Student t test;

  • Δ ANOVA;

  • Kruskal-Wallis test; NA: not applicable; —: data not available. AAU: acute anterior uveitis; axSpA: axial spondyloarthritis; NSBP: nonspecific back pain; AS: ankylosing spondylitis; ASAS: Assessment of Spondyloarthritis international Society; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; ESR: erythrocyte sedimentation rate; ASDAS-ESR: Ankylosing Spondylitis Disease Activity Score-ESR; CRP: C-reactive protein.